Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gan and Lee PharmaceuticalsSHSE:603087 -2.27%90 Dividend Payout Ratio is 1.43 as of Jun. 2026, which is 211% above its 10-year median of 0.46. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review. Among 286 Medical Devices & Instruments companies, Gan and Lee Pharmaceuticals ranks worse than 62.94% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Gan and Lee Pharmaceuticals's Dividend Payout Ratio for the
months ended in Jun. 2026 was 1.43.
The historical rank and industry rank for Gan and Lee Pharmaceuticals's Dividend Payout Ratio or its related term are showing as below:
SHSE:603087'
s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.16 Med: 0.46 Max: 0.96
Current: 0.51
During the past 13 years, the highest Dividend Payout Ratio of Gan and Lee Pharmaceuticals was 0.96. The lowest was 0.16. And the median was 0.46.
SHSE:603087's Dividend Payout Ratio is ranked worse than 62.94% of 286
companies
in the Medical Devices & Instruments industry
Industry Median: 0.41
vs SHSE:603087: 0.51
During the past 13 years, the highest Trailing Annual Dividend Yield of Gan and Lee Pharmaceuticals was 2.69%. The lowest was 0.21%. And the median was 0.83%.
During the past 12 months, Gan and Lee Pharmaceuticals's average Dividends Per Share Growth Rate was -33.30% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 49.40% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Gan and Lee Pharmaceuticals was 49.40% per year. The lowest was 20.50% per year. And the median was 34.95% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Gan and Lee Pharmaceuticals (SHSE:603087) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Gan and Lee Pharmaceuticals Dividend Payout Ratio Related Terms
Gan and Lee Pharmaceuticals Dividend Payout Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gan and Lee Pharmaceuticals Dividend Payout Ratio Chart
SHSE:603087 vs ISRG, BDX, RMD: Dividend Payout Ratio Comparison
For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gan and Lee Pharmaceuticals Dividend Payout Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Gan and Lee Pharmaceuticals's Dividend Payout Ratio falls into.
Gan and Lee Pharmaceuticals Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Gan and Lee Pharmaceuticals's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gan and Lee Pharmaceuticals (SHSE:603087) has a Dividend Payout Ratio of 1.43 as of Jun. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Gan and Lee Pharmaceuticals and its competitors. This is 211% above median its historical median of 0.46. Over the past decade, Gan and Lee Pharmaceuticals' Dividend Payout Ratio has ranged from 0.16 to 0.96. According to the industry distribution chart, Gan and Lee Pharmaceuticals ranks #180 out of 286 companies in the Medical Devices & Instruments industry, placing it in the top 62.9%.
Is Gan and Lee Pharmaceuticals' Dividend Payout Ratio too high?
Gan and Lee Pharmaceuticals' current Dividend Payout Ratio of 1.43 is 211% above median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 0.96. The Medical Devices & Instruments industry median Dividend Payout Ratio is 0.41. Gan and Lee Pharmaceuticals' value of 1.43 is 248.8% above this industry median. Based on the distribution chart, Gan and Lee Pharmaceuticals ranks #180 out of 286 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' Dividend Payout Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gan and Lee Pharmaceuticals ranks #180 out of 286 companies for Dividend Payout Ratio. This places Gan and Lee Pharmaceuticals in the lower half of its industry. The industry median Dividend Payout Ratio is 0.41. Gan and Lee Pharmaceuticals' value of 1.43 is 248.8% above this benchmark. Historically, Gan and Lee Pharmaceuticals' own Dividend Payout Ratio has ranged from 0.16 to 0.96 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.41, Gan and Lee Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Medical Devices & Instruments company?
The median Dividend Payout Ratio among Medical Devices & Instruments companies is 0.41, based on 286 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gan and Lee Pharmaceuticals's current Dividend Payout Ratio of 1.43 is 248.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Gan and Lee Pharmaceuticals and its competitors. For the Medical Devices & Instruments industry, the median Dividend Payout Ratio is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gan and Lee Pharmaceuticals's current Dividend Payout Ratio is 1.43, which is 211% above median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current Dividend Payout Ratio is 1.43, which is 211% above median its 10-year median of 0.46 and 248.8% above the Medical Devices & Instruments industry median of 0.41. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current Dividend Payout Ratio is 1.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00.
GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.
Key valuation signals for SHSE:603087:
Dividend Payout Ratio: 1.43 (211% above median its 10-year median of 0.46)
GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
Industry Position: 248.8% above the Medical Devices & Instruments median (#180 of 286)
No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603087 has been successfully added to your 
